{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:46:24Z","timestamp":1787499984719,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Michigan State University College of Veterinary Medicine Endowed Research Funds"},{"name":"Boehringer-Ingelheim Animal Health USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pituitary pars intermedia dysfunction (PPID) develops slowly in aged horses as degeneration of hypothalamic dopaminergic neurons leads to proliferation of pars intermedia (PI) melanotropes through hyperplasia and adenoma formation. Dopamine (DA) concentrations and tyrosine hydroxylase (TH) immunoreactivity are markedly reduced in PI tissue of PPID-affected equids and treatment with the DA receptor agonist pergolide results in notable clinical improvement. Thus, we hypothesized that pergolide treatment of PPID-affected horses would result in greater DA and TH levels in PI tissue collected from PPID-affected horses versus untreated PPID-affected horses.<\/jats:p>\n                    <jats:p>To test this hypothesis, pituitary glands were removed from 18 horses: four untreated PPID-affected horses, four aged and four young horses without signs of PPID, and six PPID-affected horses that had been treated with pergolide at 2 \u00b5g\/kg orally once daily for 6 months. DA concentrations and TH expression levels in PI tissues were determined by high performance liquid chromatography with electrochemical detection and Western blot analyses, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DA and TH levels were lowest in PI collected from untreated PPID-affected horses while levels in the pergolide treated horses were similar to those of aged horses without signs of PPID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings provide evidence of restoration of DA and TH levels following treatment with pergolide. Equine PPID is a potential animal model of dopaminergic neurodegeneration, which could provide insight into human neurodegenerative diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12917-020-02565-3","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T07:03:08Z","timestamp":1601017388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction"],"prefix":"10.1186","volume":"16","author":[{"given":"Jessica S.","family":"Fortin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Benskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J.","family":"Lookingland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon S.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin B.","family":"Howey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Goudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Harold C.","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"2565_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2826.2005.01277.x","volume":"17","author":"D McFarlane","year":"2005","unstructured":"McFarlane D, Dybdal N, Donaldson MT, Miller L, Cribb AE. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J Neuroendocrinol. 2005;17:73\u201380.","journal-title":"J Neuroendocrinol"},{"key":"2565_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2460\/javma.2003.223.93","volume":"223","author":"MM Brosnahan","year":"2003","unstructured":"Brosnahan MM, Paradis MR. Demographic and clinical characteristics of geriatric horses: 467 cases (1989\u20131999). J Am Vet Med Assoc. 2003;223:93\u20138.","journal-title":"J Am Vet Med Assoc"},{"key":"2565_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1354\/vp.45-1-26","volume":"45","author":"MA Miller","year":"2008","unstructured":"Miller MA, Pardo ID, Jackson LP, Moore GE, Sojka JE. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction. Vet Pathol. 2008;45:26\u201338.","journal-title":"Vet Pathol"},{"key":"2565_CR4","doi-asserted-by":"crossref","unstructured":"Schott HC 2. Pituitary pars intermedia dysfunction: equine Cushing\u2019s disease. Vet Clin North Am Equine Pract. 2002;18:237\u201370. nd. .","DOI":"10.1016\/S0749-0739(02)00018-4"},{"issue":"212\u2013217","key":"2565_CR5","first-page":"e246","volume":"24","author":"M Innera","year":"2013","unstructured":"Innera M, Petersen AD, Desjardins DR, Steficek BA, Rosser EJ Jr, Schott HC 2nd. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses. Vet Dermatol. 2013;24:212\u2013217 e246-217.","journal-title":"Vet Dermatol"},{"key":"2565_CR6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/vr.133.2.43","volume":"133","author":"JH van der Kolk","year":"1993","unstructured":"van der Kolk JH, Kalsbeek HC, van Garderen E, Wensing T, Breukink HJ. Equine pituitary neoplasia: a clinical report of 21 cases (1990\u20131992). Vet Rec. 1993;133:594\u20137.","journal-title":"Vet Rec"},{"key":"2565_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.2042-3292.1992.tb01595.x","volume":"4","author":"MH Hillyer","year":"1992","unstructured":"Hillyer MH, Taylor FGRT, Mair TS, Murphy D, Watson TDG, Love S. Diagnosis of hyperadrenocorticism in the horse. Equine Vet Edu. 1992;4:131\u20134.","journal-title":"Equine Vet Edu"},{"key":"2565_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1939-1676.1996.tb02016.x","volume":"10","author":"L Couetil","year":"1996","unstructured":"Couetil L, Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J Vet Intern Med. 1996;10:1\u20136.","journal-title":"J Vet Intern Med"},{"key":"2565_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/030098589902700606","volume":"27","author":"M Heinrichs","year":"1990","unstructured":"Heinrichs M, Baumgartner W, Capen CC. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses. Vet Pathol. 1990;27:419\u201325.","journal-title":"Vet Pathol"},{"key":"2565_CR10","first-page":"293","volume":"6","author":"CW Spelta","year":"2015","unstructured":"Spelta CW. Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management. Vet Med (Auckl). 2015;6:293\u2013300.","journal-title":"Vet Med (Auckl)"},{"key":"2565_CR11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2460\/ajvr.1999.60.02.245","volume":"60","author":"RJ Kemppainen","year":"1999","unstructured":"Kemppainen RJ, Peterson ME. Regulation of alpha-melanocyte-stimulating hormone secretion from the pars intermedia of domestic cats. Am J Vet Res. 1999;60:245\u20139.","journal-title":"Am J Vet Res"},{"key":"2565_CR12","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1210\/endo-124-5-2208","volume":"124","author":"RJ Kemppainen","year":"1989","unstructured":"Kemppainen RJ, Zerbe CA, Sartin JL. Regulation and secretion of proopiomelanocortin peptides from isolated perifused dog pituitary pars intermedia cells. Endocrinology. 1989;124:2208\u201317.","journal-title":"Endocrinology"},{"key":"2565_CR13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2460\/javma.1994.204.04.627","volume":"204","author":"NO Dybdal","year":"1994","unstructured":"Dybdal NO, Hargreaves KM, Madigan JE, Gribble DH, Kennedy PC, Stabenfeldt GH. Diagnostic testing for pituitary pars intermedia dysfunction in horses. J Am Vet Med Assoc. 1994;204:627\u201332.","journal-title":"J Am Vet Med Assoc"},{"key":"2565_CR14","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1210\/en.2018-00726","volume":"159","author":"RA Morgan","year":"2018","unstructured":"Morgan RA, Keen JA, Homer N, Nixon M, McKinnon-Garvin AM, Moses-Williams JA, Davis SR, Hadoke PWF, Walker BR. Dysregulation of Cortisol Metabolism in Equine Pituitary Pars Intermedia Dysfunction. Endocrinology. 2018;159:3791\u2013800.","journal-title":"Endocrinology"},{"key":"2565_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/cne.902440207","volume":"244","author":"PH Luppi","year":"1986","unstructured":"Luppi PH, Sakai K, Salvert D, Berod A, Jouvet M. Periventricular dopaminergic neurons terminating in the neuro-intermediate lobe of the cat hypophysis. J Comp Neurol. 1986;244:204\u201312.","journal-title":"J Comp Neurol"},{"key":"2565_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000126999","volume":"62","author":"JL Goudreau","year":"1995","unstructured":"Goudreau JL, Falls WM, Lookingland KJ, Moore KE. Periventricular-hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland. Neuroendocrinology. 1995;62:147\u201354.","journal-title":"Neuroendocrinology"},{"key":"2565_CR17","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2460\/ajvr.2005.66.2065","volume":"66","author":"D McFarlane","year":"2005","unstructured":"McFarlane D, Cribb AE. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses. Am J Vet Res. 2005;66:2065\u201372.","journal-title":"Am J Vet Res"},{"key":"2565_CR18","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1210\/endo-123-3-1598","volume":"123","author":"WR Millington","year":"1988","unstructured":"Millington WR, Dybdal NO, Dawson R Jr, Manzini C, Mueller GP. Equine Cushing\u2019s disease: differential regulation of beta-endorphin processing in tumors of the intermediate pituitary. Endocrinology. 1988;123:1598\u2013604.","journal-title":"Endocrinology"},{"key":"2565_CR19","first-page":"1133","volume":"12","author":"A Saiardi","year":"1998","unstructured":"Saiardi A, Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing\u2019s-like syndrome in mice. Mol Endocrinol. 1998;12:1133\u20139.","journal-title":"Mol Endocrinol"},{"key":"2565_CR20","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1023\/A:1007604414773","volume":"25","author":"V Calabrese","year":"2000","unstructured":"Calabrese V, Bates TE, Stella AM. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant\/antioxidant balance. Neurochem Res. 2000;25:1315\u201341.","journal-title":"Neurochem Res"},{"key":"2565_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0028-3908(01)00019-3","volume":"40","author":"Y Gilgun-Sherki","year":"2001","unstructured":"Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology. 2001;40:959\u201375.","journal-title":"Neuropharmacology"},{"key":"2565_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1089\/15230860050192224","volume":"2","author":"Y Luo","year":"2000","unstructured":"Luo Y, Roth GS. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration. Antioxid Redox Signal. 2000;2:449\u201360.","journal-title":"Antioxid Redox Signal"},{"key":"2565_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/35041687","volume":"408","author":"T Finkel","year":"2000","unstructured":"Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239\u201347.","journal-title":"Nature"},{"key":"2565_CR24","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/ene.12585","volume":"22","author":"PC Lee","year":"2015","unstructured":"Lee PC, Bordelon Y, Bronstein J, Sinsheimer JS, Farrer M, Ritz B. Head injury, alpha-synuclein genetic variability and Parkinson\u2019s disease. Eur J Neurol. 2015;22:874\u20138.","journal-title":"Eur J Neurol"},{"key":"2565_CR25","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276:2045\u20137.","journal-title":"Science"},{"key":"2565_CR26","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1046\/j.1460-9568.2000.00210.x","volume":"12","author":"AR Saha","year":"2000","unstructured":"Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Buchman VL. Induction of neuronal death by alpha-synuclein. Eur J Neurosci. 2000;12:3073\u20137.","journal-title":"Eur J Neurosci"},{"key":"2565_CR27","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.290.5493.985","volume":"290","author":"BI Giasson","year":"2000","unstructured":"Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290:985\u20139.","journal-title":"Science"},{"key":"2565_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00702-018-1903-3","volume":"126","author":"T Nagatsu","year":"2019","unstructured":"Nagatsu T, Nakashima A, Ichinose H, Kobayashi K. Human tyrosine hydroxylase in Parkinson\u2019s disease and in related disorders. J Neural Transm (Vienna). 2019;126:397\u2013409.","journal-title":"J Neural Transm (Vienna)"},{"key":"2565_CR29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/(SICI)1098-2396(199712)27:4<294::AID-SYN3>3.0.CO;2-7","volume":"27","author":"MA Silva","year":"1997","unstructured":"Silva MA, Mattern C, Hacker R, Tomaz C, Huston JP, Schwarting RK. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Synapse. 1997;27:294\u2013302.","journal-title":"Synapse"},{"key":"2565_CR30","doi-asserted-by":"publisher","first-page":"456","DOI":"10.7326\/0003-4819-83-4-456","volume":"83","author":"RD Sweet","year":"1975","unstructured":"Sweet RD, McDowell FH. Five years\u2019 treatment of Parkinson\u2019s disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med. 1975;83:456\u201363.","journal-title":"Ann Intern Med"},{"key":"2565_CR31","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.29.9_Part_1.1253","volume":"29","author":"RP Lesser","year":"1979","unstructured":"Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology. 1979;29:1253\u201360.","journal-title":"Neurology"},{"key":"2565_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000117399","volume":"37","author":"G Block","year":"1997","unstructured":"Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa\/levodopa in Parkinson\u2019s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol. 1997;37:23\u20137.","journal-title":"Eur Neurol"},{"key":"2565_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ana.410440722","volume":"44","author":"E Melamed","year":"1998","unstructured":"Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I. Levodopa toxicity and apoptosis. Ann Neurol. 1998;44:149\u201354.","journal-title":"Ann Neurol"},{"key":"2565_CR34","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/j.1471-4159.1992.tb10990.x","volume":"59","author":"B Halliwell","year":"1992","unstructured":"Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609\u201323.","journal-title":"J Neurochem"},{"key":"2565_CR35","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/mds.870120503","volume":"12","author":"AH Rajput","year":"1997","unstructured":"Rajput AH, Fenton M, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord. 1997;12:634\u20138.","journal-title":"Mov Disord"},{"key":"2565_CR36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/bmj.310.6979.575","volume":"310","author":"N Quinn","year":"1995","unstructured":"Quinn N. Drug treatment of Parkinson\u2019s disease. BMJ. 1995;310:575\u20139.","journal-title":"BMJ"},{"key":"2565_CR37","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2165\/00023210-199605050-00006","volume":"5","author":"RJ Uitti","year":"1996","unstructured":"Uitti RJ, Ahlskog JE. Comparative Review of Dopamine Receptor Agonists in Parkinson\u2019s Disease. CNS Drugs. 1996;5:369\u201388.","journal-title":"CNS Drugs"},{"key":"2565_CR38","first-page":"381","volume":"46","author":"PA Fischer","year":"1995","unstructured":"Fischer PA. Treatment strategies in Parkinson\u2019s disease after a quarter century experiences with L-DOPA therapy. J Neural Transm Suppl. 1995;46:381\u20139.","journal-title":"J Neural Transm Suppl"},{"key":"2565_CR39","first-page":"89","volume":"6","author":"WH Oertel","year":"1997","unstructured":"Oertel WH, Quinn NP. Parkinson\u2019s disease: drug therapy. Baillieres Clin Neurol. 1997;6:89\u2013108.","journal-title":"Baillieres Clin Neurol"},{"key":"2565_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/mds.870130111","volume":"13","author":"O Rascol","year":"1998","unstructured":"Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson\u2019s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord. 1998;13:39\u201345.","journal-title":"Mov Disord"},{"key":"2565_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1468-1331.1996.tb00188.x","volume":"3","author":"J Boas JWP","year":"1996","unstructured":"Boas JWP J, Dupont E, Mikkelsen B, Wermuth L. The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open\u2010label, crossover study. Eur J Neurol. 1996;3:44\u20139.","journal-title":"Eur J Neurol"},{"key":"2565_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/mds.870090409","volume":"9","author":"G Pezzoli","year":"1994","unstructured":"Pezzoli G, Martignoni E, Pacchetti C, Angeleri VA, Lamberti P, Muratorio A, Bonuccelli U, De Mari M, Foschi N, Cossutta E, et al. Pergolide compared with bromocriptine in Parkinson\u2019s disease: a multicenter, crossover, controlled study. Mov Disord. 1994;9:431\u20136.","journal-title":"Mov Disord"},{"key":"2565_CR43","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.870100522","volume":"10","author":"AM Bonnet","year":"1995","unstructured":"Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B. A \u201ccombined\u201d levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord. 1995;10:668\u201371.","journal-title":"Mov Disord"},{"key":"2565_CR44","first-page":"742","volume":"16","author":"MT Donaldson","year":"2002","unstructured":"Donaldson MT, LaMonte BH, Morresey P, Smith G, Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing\u2019s disease). J Vet Intern Med. 2002;16:742\u20136.","journal-title":"J Vet Intern Med"},{"key":"2565_CR45","doi-asserted-by":"publisher","first-page":"44154","DOI":"10.1038\/srep44154","volume":"7","author":"Y Wang","year":"2017","unstructured":"Wang Y, Sung CC, Chung KK. Novel enhancement mechanism of tyrosine hydroxylase enzymatic activity by nitric oxide through S-nitrosylation. Sci Rep. 2017;7:44154.","journal-title":"Sci Rep"},{"key":"2565_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cveq.2010.12.007","volume":"27","author":"D McFarlane","year":"2011","unstructured":"McFarlane D. Equine pituitary pars intermedia dysfunction. Vet Clin North Am Equine Pract. 2011;27:93\u2013113.","journal-title":"Vet Clin North Am Equine Pract"},{"key":"2565_CR47","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/jvp.12339","volume":"40","author":"D McFarlane","year":"2017","unstructured":"McFarlane D, Banse H, Knych HK, Maxwell LK. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction. J Vet Pharmacol Ther. 2017;40:158\u201364.","journal-title":"J Vet Pharmacol Ther"},{"key":"2565_CR48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cveq.2016.11.003","volume":"33","author":"AE Durham","year":"2017","unstructured":"Durham AE. Therapeutics for Equine Endocrine Disorders. Vet Clin North Am Equine Pract. 2017;33:127\u201339.","journal-title":"Vet Clin North Am Equine Pract"},{"issue":"Suppl 1","key":"2565_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0196-9781(88)90240-9","volume":"9","author":"DR Gehlert","year":"1988","unstructured":"Gehlert DR, Bishop JF, Schafer MP, Chronwall BM. Rat intermediate lobe in culture: dopaminergic regulation of POMC biosynthesis and cell proliferation. Peptides. 1988;9(Suppl 1):161\u20138.","journal-title":"Peptides"},{"key":"2565_CR50","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/eve.12237","volume":"26","author":"D McFarlane","year":"2014","unstructured":"McFarlane D. Pathophysiology and clinical features of pituitary pars intermedia dysfunction. Veterinary Education. 2014;26:592\u20138.","journal-title":"Veterinary Education"},{"key":"2565_CR51","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000115859","volume":"35","author":"PA Melrose","year":"1990","unstructured":"Melrose PA, Walker RF, Douglas RH. Dopamine in the cerebrospinal fluid of prepubertal and adult horses. Brain Behav Evol. 1990;35:98\u2013106.","journal-title":"Brain Behav Evol"},{"key":"2565_CR52","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbrc.2005.07.183","volume":"338","author":"H Fujisawa","year":"2005","unstructured":"Fujisawa H, Okuno S. Regulatory mechanism of tyrosine hydroxylase activity. Biochem Biophys Res Commun. 2005;338:271\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"2565_CR53","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0969-8051(03)00046-5","volume":"30","author":"J Booij","year":"2003","unstructured":"Booij J, de Bruin K, de Win MM, Lavini C, den Heeten GJ, Habraken JB. Imaging of striatal dopamine transporters in rat brain with single pinhole SPECT and co-aligned MRI is highly reproducible. Nucl Med Biol. 2003;30:643\u20139.","journal-title":"Nucl Med Biol"},{"key":"2565_CR54","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain. 2013;136:2419\u201331.","journal-title":"Brain"},{"key":"2565_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1006\/exnr.2000.7408","volume":"164","author":"KS Bankiewicz","year":"2000","unstructured":"Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000;164:2\u201314.","journal-title":"Exp Neurol"},{"key":"2565_CR56","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1602\/neurorx.2.1.129","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. Tyrosine hydroxylase replacement in experimental Parkinson\u2019s disease with transvascular gene therapy. NeuroRx. 2005;2:129\u201338.","journal-title":"NeuroRx"},{"issue":"3","key":"2565_CR57","first-page":"736","volume":"26","author":"IIHC Schott","year":"2012","unstructured":"Schott IIHC, Patterson JS, Howey EB, Benskey MJ, Goudreau JL, Lookingland KJ. Dopamine and tyrosine hydroxylase concentrations in pars intermedia tissue of horses with pituitary pars intermedia dysfunction with and without pergolide treatment. J Vet Intern Med. 2012;26(3):736.","journal-title":"J Vet Intern Med"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-020-02565-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-020-02565-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-020-02565-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T17:13:04Z","timestamp":1723655584000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-020-02565-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2565"],"URL":"https:\/\/doi.org\/10.1186\/s12917-020-02565-3","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"7 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved in advance by the Michigan State University and complied with its Institutional Animal Care and Use Committee (approval number AUF 11\/08-191-00). Horses were owned by another individual and informed written consent was obtained from all horse owners.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"356"}}